Age-related differences in phosphonoformate-induced bone toxicity in cats

• Published in: Calcified tissue international 1991-05, Vol.48 (5), p.353-361
• Main Authors: SWENSON, C. L, WEISBRODE, S. E, NAGODE, L. A, HAYES, K. A, STEINMEYER, C. L, MATHES, L. E
• Format: Article
• Language: English
• Subjects: Age Factors; Alkaline Phosphatase - blood; Animals; Biological and medical sciences; Bone and Bones - drug effects; Bone and Bones - pathology; Bone Resorption - chemically induced; Calcification, Physiologic - drug effects; Calcium - blood; Cats; Drug toxicity and drugs side effects treatment; Foscarnet; Medical sciences; Miscellaneous (drug allergy, mutagens, teratogens...); Osteomalacia - chemically induced; Pharmacology. Drug treatments; Phosphonoacetic Acid - analogs & derivatives; Phosphonoacetic Acid - toxicity; Phosphorus - blood; Rickets - chemically induced
• ISSN: 0171-967X; 1432-0827
• DOI: 10.1007/bf02556155

Phosphonoformate (PFA), a monophosphonate pyrophosphate analog, caused plasma biochemical and bone histomorphologic abnormalities in cats given 1,000 mg/kg/day as a continuous intravenous infusion for 14 days. Plasma biochemical alterations observed in young cats (10 weeks old) treated with PFA included increased calcium and decreased phosphorus, alkaline phosphatase, and calcitriol. Young cats treated with PFA developed rickets-like lesions characterized by widened growth plates, increased osteoid, and failure of mineralization. In addition, area of mineralized trabecular bone was decreased. Osteoclast size was increased whereas osteoclast perimeter and number were unaffected in young PFA-treated cats. Plasma alkaline phosphatase was decreased in adult cats (greater than or equal to 1 year old) treated with PFA but changes in calcium, calcitriol, and immunoreactive parathyroid hormone were highly variable and not significantly different. Adult cats treated with PFA exhibited osteomalacia characterized by increased osteoid area, perimeter, and width with failure of mineralization. In addition, static resorption indices were increased in PFA-treated adult cats but area of mineralized trabecular bone was not decreased. The monophosphonate PFA inhibited bone mineralization in young and adult cats similar to bisphosphonate treatment in other species. Because PFA is currently in phase I trials for use in AIDS, results of this study suggest a need to evaluate patients treated with PFA for metabolic bone disease.